Michael Geffner is Chief Medical Officer at Immunovant, Inc. (IMVT). They have made 11 open-market trades across 1 company since 2024, most recently 2025-10-22.
CIK 0002007249
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 11 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| IMVT | 217,958 | $5.8M |
Shares reported on the most recent Form 4, priced at the 2025-10-24 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| IMVT | SELL | 2025-10-22 | 2025-10-24 | $19.03 | $49K | +22.9% | +21.4% | +36.3% |
| IMVT | SELL | 2025-10-08 | 2025-10-10 | $16.30 | $21K | +10.9% | +37.1% | +54.4% |
| IMVT | SELL | 2025-07-23 | 2025-07-25 | $18.15 | $43K | -6.9% | -13.1% | +9.3% |
| IMVT | SELL | 2025-07-09 | 2025-07-11 | $17.24 | $20K | +2.2% | -18.0% | -2.9% |
| IMVT | SELL | 2025-04-23 | 2025-04-25 | $14.79 | $35K | -6.4% | -3.6% | +23.5% |
| IMVT | SELL | 2025-04-09 | 2025-04-11 | $12.99 | $160K | -0.6% | -4.0% | +15.4% |
| IMVT | SELL | 2025-01-22 | 2025-01-24 | $23.59 | $125K | -1.9% | -10.9% | -34.3% |
| IMVT | SELL | 2024-10-23 | 2024-10-25 | $29.53 | $188K | +3.3% | -11.6% | -23.1% |
| IMVT | SELL | 2024-07-24 | 2024-07-26 | $27.76 | $192K | -7.0% | +10.3% | +5.1% |
| IMVT | SELL | 2024-04-24 | 2024-04-26 | $28.90 | $188K | +8.9% | +4.0% | +1.8% |
| IMVT | SELL | 2024-01-26 | 2024-01-29 | $37.91 | $760K | -8.9% | -2.8% | -29.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.